SINGAPORE: A new study from Duke-NUS Medical School has identified a promising new avenue for tackling pulmonary fibrosis, a ...

Liver fibrosis is a major global health concern, developing as a result of chronic liver diseases (CLDs) such as viral ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...

Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions of this cell type have hardly been studied to date. Researchers have now determined that ...

Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...

It was life-changing … her lung function increased by 30 per cent,' Madi Vanstone's mom says of treatment for rare disease ...

The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety and tolerability. The study's exploratory objectives will assess the effect of RC-0315 on disease pathology, ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...